Currently, platinum-based chemotherapy with/without immunotherapy is the preferred first-line treatment in patients with advanced or metastatic HER2-mutant NSCLC; T-DXd has been approved for the same subgroup of patients after receipt of prior systemic therapy. Here, ERBB2 is linked to non-small cell lung carcinoma.